Dateline City:
TOKYO & KENILWORTH, N.J.
Combination clinical studies of lenvatinib, eribulin and pembrolizumab to be explored
TOKYO & KENILWORTH, N.J.--(BUSINESS WIRE)--Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the U.S. and
Canada, through a subsidiary, announced today a clinical trial
collaboration to evaluate the safety, tolerability and efficacy of
Mercks anti-PD-1 therapy, pembrolizumab (marketed in the U.S. under the
brand name KEYTRUDA), in combination with Eisai oncology
compounds lenvatinib mesylate (a multi-targeting RTK inhibitor marketed
in the U.S.
Language:
English
Contact:
Eisai Public Relations Department+81-(0)3-3817-5120orEisai Investor Relations+81-(0)3-3817-5327orMerck Media RelationsPamela Eisele, 267-305-3558or Claire Mulhearn, 908-236-1118orMerck Investor RelationsJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more